EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands

Maartje W. Rohaan, Marleen L. Duizer, Lot A. Devriese, Aafke Meerveld-Eggink, Willem F. Brandts, Johannes V. van Thienen, Sofie Wilgenhof, Carla M.L. van Herpen, John B.A.G. Haanen

EJC Skin Cancer · 2023

DOI: 10.1016/j.ejcskn.2023.100007 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift EJC Skin Cancer, 2023. Verfasst von Maartje W. Rohaan und 8 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous squamous cell carcinoma (CSCC) is the second most common cutaneous malignancy and patients with advanced disease have a poor prognosis. Phase I/II clinical studies have shown the efficacy of cemiplimab, a monoclonal anti-PD-1 antibody, for this disease. However, real-world data on tolerability and clinical outcome in larger patient populations is needed to aid clinical decision-making.

Methods

In this retrospective cohort study, patients treated with flat dose cemiplimab 350 mg Q3W intravenously for advanced CSCC (aCSCC) from three centers in the Netherlands were retrospectively investigated. Adverse events (AE), tumor response, progression-free survival (PFS) and overall survival (OS) were assessed.

Results

In total, 65 patients (median age 76; range 30–93 years) with locally advanced (29 patients [45%]) or metastatic (36 patients [55%]) CSCC were included. All but 8 patients (88%) had comorbidities and 58 patients (89%) did not receive any prior systemic therapy. Treatment was well-tolerated, with grade 3–4 AEs in 22% of patients. An objective response was seen in 34 patients (52%), of whom 14 (22%) reached a complete response. With a median follow-up of 21.5 months, the median PFS was 10.9 (95% CI, 1.8–20.0) and median OS was 26.1 months.

Conclusions

In this real-world cohort of aCSCC patients from the Netherlands, cemiplimab demonstrated to be well-tolerated, even in elderly patients with severe comorbidities, achieving an objective response in 52% of patients. This outcome was comparable to the results of prospective clinical trials.

Zitieren

APA

Rohaan, M. W., Duizer, M. L., Devriese, L. A., Meerveld-Eggink, A., Brandts, W. F., Thienen, J. V. V., Wilgenhof, S., Herpen, C. M. V., & Haanen, J. B. (2023). Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands. EJC Skin Cancer. https://doi.org/10.1016/j.ejcskn.2023.100007

Vancouver

Rohaan MW, Duizer ML, Devriese LA, Meerveld-Eggink A, Brandts WF, Thienen JVV, et al. Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands. EJC Skin Cancer. 2023. doi:10.1016/j.ejcskn.2023.100007

BibTeX
@article{Rohaan2023,
  author = {Rohaan, Maartje W. and Duizer, Marleen L. and Devriese, Lot A. and Meerveld-Eggink, Aafke and Brandts, Willem F. and Thienen, Johannes V. van and Wilgenhof, Sofie and Herpen, Carla M.L. van and Haanen, John B.A.G.},
  title = {Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands},
  journal = {EJC Skin Cancer},
  year = {2023},
  doi = {10.1016/j.ejcskn.2023.100007}
}
Kostenlos starten →